Aparato Locomotor

VOL.18 Nº3, JULIO/SEPTIEMBRE 2007

ImprimirImprimir

Therapeutical angiogenesis in patients with critical leg ischemia.
Phase II study with injection of AC133+ cells mobilized with G-CSF from peripheral blood. Follow-up of three first cases

Barros M. B.1, González Porras J. R.2,
Sánchez-Guijo F. M.2, del Cañizo M. C.2 ,
Lozano F. S.1

1 Servicio de Angiología y Cirugía Vascular
2 Servicio de Hematología y Unidad de Terapia Celular
Hospital Clínico Universitario de Salamanca
Universidad de Salamanca

Introduction: Chronical arterial disease (CAD) is an extremely incapacitating illness which affects 3-5% of the male population above 60 years-old. Actually, cell therapy is an alternative that causes great expectation for the treatment of the peripheral ischemias. The aim of the present study was to analyze the efficiency and security of autologous AC133+ cells on promoting limb revascularization in patients with critical CAD.

Material and Methods: Three patients with critical CAD were included and followed up to date. The patients were subjected to mobilization of hematopoietic precursors from the bone marrow to peripheral blood with G-CSF. Later, the autologous endothelial stem cells AC133+, extracted and selected from blood through the CliniMACS® (Miltenyi Biotec) system, were injected intramuscularly. The patients were followed for 6 months as the study’s protocol and clinical, functional, hemodynamic, anatomical and quality of life variables were evaluated.

Results: The process of mobilization, collection and infusion of the endothelial stem cells was well tolerated. Through the follow-up there were no amputations and there was objective as well as subjective improvement of some studied variables.

Conclusion: So far and with three included patients, the process of administration of the AC133+ cells has shown security and lack of complication, although we have to be cautious on correlating cell therapy with clinical improvement. With the inclusion of new patients and their mid term follow-up we shall clarify the clinical effect of the AC133+ cells.

Correspondencia:

M. B. Barros. Dpto. de Cirugía. Facultad de Medicina
Avda Alfonso X El Sabio s/n. 37007 Salamanca.
marcellobb@bol.com.br

Beca Larramendi (FUNDACIÓN MAPFRE y Fundación Española de Hematología y Hemoterapia (FEHH)

MAPFRE MEDICINA, 2007; 18 (3): 180-189


Icono de conformidad con el Nivel Doble-A, de las Directrices de Accesibilidad para el Contenido Web 1.0 del W3C-WAI